309 related articles for article (PubMed ID: 21674503)
1. PSCA mRNA expression in preoperatively negative prostate biopsies predicts incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Ma W; Zeng G; Qi D
J Surg Oncol; 2011 Nov; 104(6):672-8. PubMed ID: 21674503
[TBL] [Abstract][Full Text] [Related]
2. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
3. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
Zhigang Z; Wenlu S
Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
[TBL] [Abstract][Full Text] [Related]
4. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
Zhigang Z; Wenlu S
Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
[TBL] [Abstract][Full Text] [Related]
5. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.
Zhigang Z; Wenlu S
Prostate; 2005 Dec; 65(4):299-305. PubMed ID: 16015594
[TBL] [Abstract][Full Text] [Related]
6. Serum early prostate cancer antigen (EPCA) as a significant predictor of incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Zeng G; Zhong W
Prostate; 2010 Dec; 70(16):1788-98. PubMed ID: 20583137
[TBL] [Abstract][Full Text] [Related]
7. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
Zhigang Z; Wenlv S
Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
[TBL] [Abstract][Full Text] [Related]
8. Prostate stem cell antigen (PSCA) mRNA expression in prostatic intraepithelial neoplasia: implications for the development of prostate cancer.
Zhigang Z; Wenlu S
Prostate; 2007 Aug; 67(11):1143-51. PubMed ID: 17503471
[TBL] [Abstract][Full Text] [Related]
9. Prostate stem cell antigen (PSCA) mRNA expression in peripheral blood in patients with benign prostatic hyperplasia and/or prostate cancer.
Fawzy MS; Mohamed RH; Elfayoumi AR
Med Oncol; 2015 Mar; 32(3):74. PubMed ID: 25698533
[TBL] [Abstract][Full Text] [Related]
10. TP53 mutation in prostate needle biopsies--comparison with patients follow-up.
Ecke TH; Schlechte HH; Hübsch A; Lenk SV; Schiemenz K; Rudolph BD; Miller K
Anticancer Res; 2007; 27(6B):4143-8. PubMed ID: 18225585
[TBL] [Abstract][Full Text] [Related]
11. Role of transurethral biopsy sampling of the prostate to diagnose prostate cancer in men undergoing surgical intervention for benign prostatic hyperplasia.
Bales GT; Flynn TJ; Kynaston HG; Golash A; Hart A; Kim HL; Gerber GS
Tech Urol; 2000 Sep; 6(3):201-4. PubMed ID: 10963487
[TBL] [Abstract][Full Text] [Related]
12. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
13. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer.
Zhigang Z; Wenlv S
World J Surg Oncol; 2004 May; 2():13. PubMed ID: 15132743
[TBL] [Abstract][Full Text] [Related]
14. Prostate stem cell antigen mRNA in peripheral blood as a potential predictor of biochemical recurrence in high-risk prostate cancer.
Joung JY; Cho KS; Kim JE; Seo HK; Chung J; Park WS; Choi MK; Lee KH
J Surg Oncol; 2010 Feb; 101(2):145-8. PubMed ID: 20039280
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood reverse transcription PCR assay for prostate stem cell antigen correlates with androgen-independent progression in advanced prostate cancer.
Zhao Z; Zeng G; Ma W; Ou L; Liang Y
Int J Cancer; 2012 Aug; 131(4):902-10. PubMed ID: 21952944
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of high-grade prostatic intraepithelial neoplasia in transurethral resection specimens.
Pacelli A; Bostwick DG
Urology; 1997 Sep; 50(3):355-9. PubMed ID: 9301697
[TBL] [Abstract][Full Text] [Related]
17. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
18. "Finding the needle in a haystack": oncologic evaluation of patients treated for LUTS with holmium laser enucleation of the prostate (HoLEP) versus transurethral resection of the prostate (TURP).
Herlemann A; Wegner K; Roosen A; Buchner A; Weinhold P; Bachmann A; Stief CG; Gratzke C; Magistro G
World J Urol; 2017 Nov; 35(11):1777-1782. PubMed ID: 28516315
[TBL] [Abstract][Full Text] [Related]
19. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J
Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487
[TBL] [Abstract][Full Text] [Related]
20. Reverse transcriptase-polymerase chain reaction and immunohistochemical studies for detection of prostate stem cell antigen expression in prostate cancer: potential value in molecular staging of prostate cancer.
Joung JY; Yang SO; Jeong IG; Han KS; Seo HK; Chung J; Park WS; Lee KH
Int J Urol; 2007 Jul; 14(7):635-43. PubMed ID: 17645609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
